Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology

Mol Oncol. 2010 Dec;4(6):496-510. doi: 10.1016/j.molonc.2010.09.001. Epub 2010 Sep 16.


Emerging proteomic tools and mass spectrometry play pivotal roles in protein identification, quantification and characterization, even in complex biological samples. The cancer secretome, namely the whole collection of proteins secreted by cancer cells through various secretory pathways, has only recently been shown to have significant potential for diverse applications in oncoproteomics. For example, secreted proteins might represent putative tumor biomarkers or therapeutic targets for various types of cancer. Consequently, many proteomic strategies for secretome analysis have been extensively deployed over the last few years. These efforts generated a large amount of information awaiting deeper mining, better understanding and careful interpretation. Distinct sub-fields, such as degradomics, exosome proteomics and tumor-host cell interactions have been developed, in an attempt to provide certain answers to partially elucidated mechanisms of cancer pathobiology. In this review, advances, concerns and challenges in the field of secretome analysis as well as possible clinical applications are discussed.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Computational Biology / methods
  • Databases, Protein
  • Disease Progression
  • Humans
  • Inflammation / metabolism
  • Neoplasm Metastasis
  • Neoplasm Proteins / metabolism*
  • Neoplasms* / metabolism
  • Neoplasms* / pathology
  • Neoplasms* / physiopathology
  • Proteomics / methods*


  • Biomarkers, Tumor
  • Neoplasm Proteins